Telemedinsk udvikling

Similar documents
Decision systems in quality registries

Evidence of Crohn s Disease. Case Presentation

How To Treat Colitis With A Combination Of Antibiotics

Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms. Stephen B. Hanauer, M.D. University of Chicago

Measuring severity of disease and defining treatment benefit using the Simple Endoscopic Activity Score (SES-CD)

What are the Unmet Needs in the Management of IBD?

Proposal to Establish the Crohn s and Colitis Center at the University of Miami Miller School of Medicine

Crohn s and Colitis Center

Research in IBD at University of Colorado Denver

TREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER

Leukapheresis for inflammatory bowel disease

Understanding Colitis and Crohn s Disease

Probiotics for the Treatment of Adult Gastrointestinal Disorders

Focus Biobank Inflammatory Bowel Disease

Terapia con farmaci biologici e non nella. Sandro Ardizzone. Azienda Ospedaliera Fatebenefratelli e. Ospedale di Rilievo Nazionale Milan

Briefing Document. Food and Drug Administration. Center for Drug Evaluation and Research

The Oxford IBD Service

How long will it take to work? You may begin to feel better within a few days or it may take up to six weeks after your first treatment session.

Inflammatory Bowel Disease

Medical Therapy for IBD

Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes. Dr. med. Henrik Csaba Horváth

Health Service Development Manager (Specialist Nursing)

Crohn's disease and pregnancy.

IBS TREATMENT CENTER

INFLAMMATORY BOWEL DISEASE

MY CROHN S AND COLITIS CARE YOUR GUIDE

2. FRAGESTELLUNGEN DER VORGESTELLTEN ARBEITEN Wirksamkeit der Akupunktur bei ausgewählten Schmerzerkrankungen

Pediatric Gastroenterology Fellowship Pediatric Nutrition Rotation Goals and Objectives - 1 st Year

Midterm Final US S E NA Applies principles of epidemiology and demography in clinical practice.

EVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze

An Overview of the Management of Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) Sue Surgenor October 6 th 2015

Adult Inflammatory Bowel Disease Physician Performance Measures Set. August 2011*

Original Policy Date

Connect4 Patients CCCM Primary Care Community. Presented By: Veronica Mansfield, DNP, APRN, AE-C, CCM Kit McKinnon, MBA, BSN, RN, CDE, CCM

REVIEW. Am J Gastroenterol advance online publication, 2 November 2010; doi: /ajg

Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy

Pre-Budget Consultation Submission to the Standing Committee on Finance. August 6 th, 2014

Ulcerative Colitis & Proctitis. About Ulcerative Colitis & Proctitis

This fact sheet was adapted from

Microscopic Colitis: Collagenous Colitis and Lymphocytic Colitis

Gut Decisions. Leading change to improve the lives of people with Crohn s and colitis

Positive Coping with Rheumatoid Arthritis a skills workshop

International Journal of Recent Advances in Multidisciplinary Research Vol. 02, Issue 12, pp , December, 2015

Informatics: Opportunities & Applications. Professor Colin McCowan Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit

Addiction Billing. Kimber Debelak, CMC, CMOM, CMIS Director, Recovery Pathways

INFLAMMATORY BOWEL DISEASE (IBD) MEASURES GROUP OVERVIEW

GENOTYPE AND PHENOTYPE, PREGNANCY AND DISEASE COURSE A European cohort study of IBD patients

Biologic Treatments for Rheumatoid Arthritis

IBD Standards 2013 Update

PATRICK HANAWAY, M.D.

Media Release. Basel, 11 June RA patients with enhanced response identified

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

QS114. NICE quality standard for irritable bowel syndrome in adults (QS114)

Trauma-Informed Care Innovation Community Webinar #4: Building Trusting Relationships through Safe Interactions and Peer Support

Recovery and Dual Diagnosis

Digestive and Liver Disease

Facilitating Behavior Change

Workshop on Patient Support and Market Research Programmes

In vitro co-culture model of the inflamed intestinal mucosa

Antidepressant Work Dealing with Mood Problems in the Workplace

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

TELEMEDICINE A KEY TO HEALTH SERVICES OF THE FUTURE

Guide to Abdominal or Gastroenterological Surgery Claims

P A T H W A Y S T O A. Career in. Sports Medicine

What Is Clostridium Difficile (C. Diff)? CLOSTRIDIUM DIFFICILE (C. DIFF)

Overcoming Resistance to Stopping Tobacco Use: A Motivational Approach

Assessment of depression in adults in primary care

Patient Reported Outcome Data: Why PROs Will Be The Next Wave in Big Data. Neil B. Minkoff, M.D. Chief Medical Officer EmpiraMed

Celiac Disease. Donald Schoch, M.D. Ohio ACP Meeting October 17, 2014

Rheumatoid Arthritis

HIV Outpatient Clinical Care Pathway Version 11 [As per 10 updated for documentation review]

Transcription:

F A C UL T Y O F HE AL T H A ND ME D I C A L S C I E N C E S U N I V E R S I T Y O F C O P E N H A G E N Telemedinsk udvikling Motivational Interviewing Sygeplejerskens rolle - i centrum af ehealth Fagligt Selskab for Gastroenterologiske Sygeplejersker Professor Pia Munkholm & IBD specialist nurse Dorte Marker University of Copenhagen

Motivational Interviewing Network of Trainers William R. Miller and Stephen Rollnick in Virginia, USA (2008) Interest: to improve the quality and effectiveness of counseling & consultations with clients about behavior change. Research focus on: Good practice in efforts to promote change and behaviour change among patients, clients and the practitioners who serve them(1998) Motivation is not seen as static but as dynamic. It is purposeful, intentional, and positive-directed toward the best interest of self (1983) Stepen Rollnick, Professor of Healthcare Communication at Cardiff University, clinical psychologist

DEEP-Danish Ehealth & Epidemiology group UC SCCAI 43/55% Agressive 20% Agressive 9% agressive: relapse every year 3/1% FC Moderate 36% Moderate 70% Moderate: Half of the years in inactive stage 19/6% Indolent 44% Mild 21% Mild-indolent: Inactive since diagnosis or the majority of the years 32/37% TIBS= SCCAI + FC Crohns disease/ulcerative colitis 8 years Crohns disease/ulcerative colitis 10 years Deep remission SCCAI <1 FC<100mg/kg P Munkholm SJG 1995, E Langholz Gastro 1994(UC) IC Solbjerg. CGH 2007(CD); SJG 2009(UC) Pedersen N. IBD 2014, DMJ 2015, Elkjaer M. DMJ 2012

Study methods: assessment of damage Extent x Severity

Digestive Damage Progression of digestive disease damage (Lémann score) and inflammatory activity Stricture Fistula/abscess Surgery Stricture Inflammatory Activity (CDAI, CDEIS, CRP) Disease onset Pre-clinical Diagnosis Early disease Clinical CDAI: Crohn's Disease Activity Index; CDEIS : Crohn s Disease Endoscopic Index of Severity; CRP: C-Reactive Protein Pariente B et al. Inflamm Bowel Dis 2011;17(6):1415-22

Download for free www.dmj.dk

Web-epidemiology & web-applications EPIDEMIOLOGIC web-databases 1. Povl Riis 1958-87, FU 1997 2. DCCD; Danish Crohn Colitis Database 1998-2014 3. EpiCom, European Database 2010-2015, 32 centre, web epidemiological database 4. CSO, MD, Ph.D Johan Burisch burisch@gmail.com ehealth web-applications www.constant-care.dk(uc any 5asa) 2 www.cd.constant-care.dk (CD IFX) 4 www.meza.constant-care.dk(mmx meza) 3 www.ibs.constant-care.dk(lowfodmap) 5 www.ibs-ibd.constant-care.dk(lfd) www.young.constant-care.dk(ibd children) www.egastro.constant-care.dk(kih any) 1 www.ibs-c.constant-care.dk(constipation) www.cd-ada.constant-care.dk(adalimumab) 6 Elkjaer M. EJGH 2009

Why ehealth? SMART phone Fecal Calprotectin Homemoni toring Disease activity Selfinitiate Compliance Adherence

ehealth adjuvant & achivement Goal Mucosal healing Change of natural disease course Adherence/compliance QoL PRO personal reported out-come Recognition of a relapse Self-initiate 5asa high dose for 1 month Shorten time to remission Acheivements 2014 IBD, IBS & IBS-IBD Mucosal healing by FC, fecal calprotectin NDC-yet to be proven long-term Adherence/compliance QoL PRO by web-app solution Recognition of a relapse Self-initiate 5asa high dose for 1 month Shorten time to remission Elkjaer M. Dan Med J 2012, Pedersen N. Dan Med J 2013

TRAFIC LIGHT WEB-APPLICATION Elkjaer M. APT 2009 Self-initiated MMX Mezavant 12 weeks Pedersen N. IBD 2014, Elkjaer M. EJGH 2010

Can we during partner ship deminish disease activity over time? Change of the natural disease score MD Standard care WEB-Doctor ibd nurse/patient Conventionel Course ehealth web-app

ehealth: diminish inflammation burden? Disease course: Standard care ehealth web-app Treatment begin Days(range) 0 78 days (range (46-108) 0 17 days 0 10 days 0 7 days (range 10-21) MD WEB DOCTOR/PATIENT/NURSE Elkjaer M. GUT 2010

Clinical Integrated Home Monitoring Home-monitoring, screening 1 -symptomscore -fecal calprotectin CIH Patient contact/ IBD nurse IBD Call center Standard therapy Hospital visit with monitoring at outpatient clinic -symptomscore -feces calprotectin 0 6 month Vinding KK, Marker D. 2014 in progress

egastro, CIH: Lead time bias 1 ehealth influencing time, disease course & disease damage WEB group n=125 pts Home monitoring: symptomscore + Feces Relapse confirmed by trafic light scoring Lead time Crohn & Colitis ulcerosa randomised Expected remission-time Standard care, no screening CONTROL n=125 pts Relapse bleeding/pain Relapse confirmed only by symprtomscore at out-patient clinic Consultation & treatment Expected remission-time Inactive disease No symptoms/bleeding/pain

ehealth: UC 1 year any 5-asa 2 Elkjaer M. GUT & Dan Med J 2012

ehealth: UC non-adherent to 5-asa 3 QoL Fecal Calprotectin SCCAI Pedersen N. IBD 2014 & Dan Med J 2015

ehealth: Crohns infliximab 1 year 4 QoL Inflammation Burden Pedersen N. APT 2012

5 ehealth: IBS IBS lowfodmap, Lactobac Rhamnosus, Danish nutrition Pedersen N. WJG 2014 & 2015

ehealth: IBS-IBD 6 Pedersen N. WJG 2015, GUT 2015, Dan Med J 2015

ehealth: IBS-IBD decreasing of FODMAPS (gram) 6 Pedersen N. WJG 2015, GUT 2015, Dan Med J 2015

Future ehealth ehealth CIH-Clinical Integrated Homemonitoring Standard care egastro egravid u- og kompliceret ekol ediabetes ehealth Homemonitoring & individualized therapy Patient empowerment compliance Self-initiated treatment 5asa Treat to target-mucosa healing Health platform EPIC Patient access Staff access

Tak Invitation: Phd forsvar PANUM 16/1-15, kl 14 Dorte Marker, forskningssygeplejerske Hanne Fuglsang, bioanalytiker Tina Sørensen, bioanalytiker Tine Thokilgaard, stud med Louise Maagaard, stud med Line Molzen, stud med Henriette Elsberg, stud med Sara Al-Nawas, stud med Zsuzsanna Vegh, MD (Hungary) Johan Burisch, ph.d., læge Kristoffer Kofod Vinding, læge, ph.d. stud. Katrine Carlsen, læge, Ph.d. stud. Natalia Pedersen, overlæge, Phd Pia Munkholm, Professor